M

    Mineralys Therapeutics, Inc. Common Stock (MLYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.67
    +0.07 (+0.27%)

    Market Cap: $2.27B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(9/15)
    Avg Surprise
    -13.68%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.53
    Range$-0.61 - $-0.44
    8 analysts
    EPS Revisions
    1
    0
    7d
    0
    5
    30d
    EPS Estimate Drift
    90d ago$-0.47+13.0%
    60d ago$-0.54-0.4%
    30d ago$-0.54-0.1%
    7d ago$-0.54-0.1%
    Current$-0.53
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.92
    Range$-3.12 - $-2.42
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.92---
    Sep 26EST
    		-$-0.53---
    Jun 26
    Reported Aug 11
    		$-2.85$-0.57-400.00%Miss-331.8%
    Mar 26
    Reported May 6
    		$-0.47$-0.44-6.82%Miss+40.5%
    Dec 25
    Reported Mar 12
    		$-0.40N/A+57.45%Beat+59.2%
    Sep 25
    Reported Nov 10
    		$-0.52$-0.61+14.75%Beat+54.0%
    Jun 25
    Reported Aug 12
    		$-0.66$-0.74+10.81%Beat+20.5%
    Mar 25
    Reported May 12
    		$-0.79$-0.98+19.39%Beat-12.9%
    Dec 24
    Reported Feb 12
    		$-0.98$-1.08+9.26%Beat-60.7%
    Sep 24
    Reported Nov 11
    		$-1.13$-0.83-36.14%Miss-98.2%
    Jun 24
    Reported Aug 13
    		$-0.83$-0.70-18.57%Miss-167.7%
    Mar 24
    Reported May 9
    		$-0.70$-0.67-4.48%Miss-37.3%
    Dec 23
    Reported Mar 21
    		$-0.61$-0.82+25.61%Beat+64.9%
    Sep 23
    Reported Nov 7
    		$-0.57$-0.76+25.00%Beat-
    Jun 23
    Reported Aug 7
    		$-0.31N/A+56.94%Beat-
    Mar 23
    Reported May 15
    		$-0.51$-0.89+42.70%Beat-
    Dec 22
    Reported Feb 10
    		$-1.74$-1.72-1.16%Miss-

    Key Metrics

    Valuation
    P/E Ratio-6.05EV/EBITDA-7.41x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-80.90%ROIC-45.16%
    Financial Health
    Debt/Equity0.18xInterest CoverageN/A
    Current Ratio34.46xQuick Ratio34.46x
    Trading Statistics
    Beta0.68Avg Volume787.70K
    52-Week High$47.6552-Week Low$22.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.97
    SMA 20$26.35
    SMA 50$26.84
    SMA 200$29.94
    EMA 10$25.94
    EMA 20$26.19
    EMA 50$26.60
    EMA 200$27.51

    MACD

    Line: -0.30Signal: -0.26Hist: -0.05

    ADX

    ADX: 11.5+DI: 18.0-DI: 24.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down20.0
    PSAR$27.48

    Bollinger Bands

    Upper Band$27.70
    Lower Band$25.00
    %B Position1024%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    44.3

    Momentum Oscillators

    Stoch %K27.3
    Stoch %D30.7
    Williams %R-74.7
    ROC (10d)-1.5%
    Momentum-0.38
    CCI (20d)-90.5
    MFI (14d)43.0

    Volatility Measures

    ATR (14d)$1.10(4.3%)
    StdDev (20d)0.67
    Hist Vol33.1%(Moderate)

    Volume Flow

    VWAP$25.56
    OBV18.1M
    AD Line24.9M
    CMF (20d)0.060

    Volume Metrics

    Avg Vol (20d)775.5K
    Vol Ratio1.2x
    VWMA (20d)$26.37

    Pivot Points

    R3$26.91
    R2$26.51
    R1$26.05
    Pivot Point$25.65
    S1$25.20
    S2$24.80
    S3$24.34

    Advanced Oscillators

    TSI-9.55
    Ultimate Osc50.4
    KST-39.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$34,000$0$0$0$0$0
    Cost of Revenue$0$0$13,000$0$0$0$17,000$0$0$0N/A$0
    Gross Profit$0$0$-13,000$0$0$0$17,000$0$0$0N/A$0
    Operating Expenses$246.04M$45.34M$38.28M$41.13M$46.75M$44.45M$51.77M$60.11M$45.17M$35.36M$27.71M$26.27M
    R&D$221.38M$24.36M$24.40M$31.45M$38.28M$37.88M$44.57M$53.98M$39.27M$30.75M$23.68M$22.50M
    SG&A$24.66M$20.98M$13.88M$9.68M$8.47M$6.57M$7.20M$6.12M$5.89M$4.61M$4.03M$3.77M
    Operating Income$-246,040,000$-45,340,000$-38,280,000$-41,131,000$-46,746,000$-44,447,000$-51,767,000$-60,106,000$-45,168,000$-35,362,000$-27,711,000$-26,273,000
    Interest Income$4.96M$6.00M$6.04M$4.20M$3.47M$2.24M$2.81M$3.77M$4.15M$3.85M$3.32M$3.51M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-241,071,000$-39,339,000$-32,234,000$-36,932,000$-43,274,000$-42,211,000$-48,946,000$-56,342,000$-41,014,000$-31,508,000$-24,389,000$-22,760,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-241,071,000$-39,339,000$-32,234,000$-36,932,000$-43,274,000$-42,211,000$-48,946,000$-56,342,000$-41,014,000$-31,508,000$-24,389,000$-22,760,000
    EBITDA$-250,539,000$-49,954,000$-42,474,000$-43,508,000$-48,961,000$-45,481,000$-53,077,000$-62,817,000$-48,004,000$-37,862,000$-29,777,000$-28,235,000
    EBIT$-246,027,000$-45,335,000$-38,279,000$-41,127,000$-46,748,000$-44,450,000$-51,755,000$-60,116,000$-45,166,000$-35,361,000$-27,711,000$-26,273,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MLYS

    News

    Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com

    Eric Warren, Chief Commercial Officer at Mineralys Therapeutics, sold 7,437 shares of the company's common stock for $193,188, following the exercise of stock options. These transactions occurred under a Rule 10b5-1 selling plan. The company recently reported a wider-than-expected loss for Q2 2026, driven by investments in its blood pressure drug, lorundrostat.

    Investing.com Australia•8/26/26•
    Neutral

    Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan

    Mineralys Therapeutics, Inc. (MLYS) Chief Commercial Officer Eric Warren sold 7,437 shares of common stock at a weighted-average price of $25.9767 per share on August 21, 2026, following the exercise of stock options. These transactions were conducted under a Rule 10b5-1 stock selling plan adopted on March 27, 2026. After the sale, Warren holds 238,001 stock options and 38,400 common shares directly.

    Stock Titan•8/25/26•
    Neutral

    Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal

    Mineralys Therapeutics, Inc. (MLYS) officer Eric Warren has filed a Rule 144 notice to sell 7,437 shares of common stock on August 21, 2026, stemming from the exercise of employee stock options. This planned sale follows two previous sales by Warren within the last three months, totaling 104,124 shares for $2,696,321.98 on June 26, 2026, and 7,438 shares for $199,884.80 on July 21, 2026. The upcoming transaction has an aggregate market value of $193,188.40.

    Stock Titan•8/21/26•
    Neutral

    People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management

    Mineralys Therapeutics, Inc. has appointed Jessica Wagner Keliher, SPHR, as Vice President, Talent Management. Keliher brings over two decades of human resources leadership experience from the biotech and life sciences sectors, including previous roles at Cartesian Therapeutics, Novavax, and Kite Pharma. Her new role will focus on shaping the people and culture strategy as Mineralys Therapeutics prepares for the commercialization of its lead hypertension treatment, Lorundrostat.

    BioBuzz•8/19/26•
    Bullish

    A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56

    This article provides a snapshot of analyst ratings for Mineralys Therapeutics (MLYS.US), with forecasts ranging from $40 to $56. It offers insights into the company's market position and future financial expectations from various financial institutions.

    Moomoo•8/19/26•
    Somewhat-Bullish

    Frequently Asked Questions About MLYS

    Does MLYS pay dividends?
    Mineralys Therapeutics, Inc. Common Stock (MLYS) does not currently pay a regular dividend.
    What is MLYS's market cap?
    Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market capitalization of $2.27B with a current stock price of $25.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In